2023. Pre-treatment of the beta3-adrenergic receptor agonist BRL37344 reduces in vivo myocardial ischemia/reperfusion injury by improving AMPK and SIRT1 activity and by suppressing mTOR and p70S6K signaling pathways. Brazilian Journal of Pharmaceutical Sciences. 59, (Nov. 2023), e23002. DOI:https://doi.org/10.1590/s2175-97902023e23002.